Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review

  • ID: 4284627
  • SWOT Analysis
  • 49 pages
  • GlobalData
  • Concert Pharmaceuticals Inc
1 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Axsome Therapeutics Inc
  • Hikma Pharmaceuticals Plc
  • LEO Pharma A/S
  • Lundbeck LLC
  • MORE
Concert Pharmaceuticals Inc (CNCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorphan) indicated for alzheimer’s agitation, major depressive disorder and residual schizophrenia; CTP-730 (deuterated apremilast) for inflammatory diseases; CTP-692, a selective DCE modified analog of the endogenous amino acid, D-serine for Schizophrenia, and JZP-386 (deuterated sodium-oxybate) for narcolepsy. It employs its deuterated compounds to reduce the extent of metabolism in the wall of the intestines and in the liver. Concert Pharmaceuticals is headquartered in Lexington, Massachusetts, the US.

Concert Pharmaceuticals Inc Key Recent Developments

Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
Jan 12, 2018: Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Axsome Therapeutics Inc
  • Hikma Pharmaceuticals Plc
  • LEO Pharma A/S
  • Lundbeck LLC
  • MORE
Section 1 - About the Company
  • Concert Pharmaceuticals Inc - Key Facts
  • Concert Pharmaceuticals Inc - Key Employees
  • Concert Pharmaceuticals Inc - Key Employee Biographies
  • Concert Pharmaceuticals Inc - Major Products and Services
  • Concert Pharmaceuticals Inc - History
  • Concert Pharmaceuticals Inc - Company Statement
  • Concert Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Concert Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Concert Pharmaceuticals Inc - Corporate Strategy
  • Concert Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Concert Pharmaceuticals Inc - Strengths
  • Concert Pharmaceuticals Inc - Weaknesses
  • Concert Pharmaceuticals Inc - Opportunities
  • Concert Pharmaceuticals Inc - Threats
  • Concert Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Concert Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
  • Jan 12, 2018: Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
  • Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
  • Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
  • Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
  • Aug 08, 2017: Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
  • May 30, 2017: Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws
  • May 02, 2017: Concert Pharmaceuticals Reports First Quarter 2017 Financial Results
  • Mar 06, 2017: Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Concert Pharmaceuticals Inc, Key Facts
  • Concert Pharmaceuticals Inc, Key Employees
  • Concert Pharmaceuticals Inc, Key Employee Biographies
  • Concert Pharmaceuticals Inc, Major Products and Services
  • Concert Pharmaceuticals Inc, History
  • Concert Pharmaceuticals Inc, Subsidiaries
  • Concert Pharmaceuticals Inc, Key Competitors
  • Concert Pharmaceuticals Inc, Ratios based on current share price
  • Concert Pharmaceuticals Inc, Annual Ratios
  • Concert Pharmaceuticals Inc, Annual Ratios
  • Concert Pharmaceuticals Inc, Annual Ratios
  • Concert Pharmaceuticals Inc, Interim Ratios
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Concert Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Concert Pharmaceuticals Inc, Performance Chart (2013-2017)
  • Concert Pharmaceuticals Inc, Ratio Charts
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • SyneuRx International Corp
  • Otsuka Pharmaceuticals (U.K.) Ltd
  • Lundbeck LLC
  • LEO Pharma A/S
  • Intra-Cellular Therapies Inc
  • Hikma Pharmaceuticals Plc
  • Axsome Therapeutics Inc
  • Aclaris Therapeutics Inc
  • Acadia Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll